Pharmacokinetics of Oral and Inhaled Terbutaline after Exercise in Trained Men by Anders Dyreborg et al.
ORIGINAL RESEARCH
published: 10 June 2016
doi: 10.3389/fphar.2016.00150
Frontiers in Pharmacology | www.frontiersin.org 1 June 2016 | Volume 7 | Article 150
Edited by:
Narasaiah Kolliputi,
University of South Florida, USA
Reviewed by:
Stephen J. Fowler,
The University of Manchester, UK
Nadia Mores,
Catholic University of the Sacred
Heart, Italy
*Correspondence:
Morten Hostrup
mhostrup@nexs.ku.dk
Specialty section:
This article was submitted to
Respiratory Pharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 15 February 2016
Accepted: 24 May 2016
Published: 10 June 2016
Citation:
Dyreborg A, Krogh N, Backer V,
Rzeppa S, Hemmersbach P and
Hostrup M (2016) Pharmacokinetics
of Oral and Inhaled Terbutaline after
Exercise in Trained Men.
Front. Pharmacol. 7:150.
doi: 10.3389/fphar.2016.00150
Pharmacokinetics of Oral and
Inhaled Terbutaline after Exercise in
Trained Men
Anders Dyreborg 1, Nanna Krogh 1, Vibeke Backer 1, 2, Sebastian Rzeppa 3,
Peter Hemmersbach 3 and Morten Hostrup 1, 2, 4*
1 Respiratory Research Unit, Bispebjerg Hospital, Copenhagen, Denmark, 2 IOC Sports Medicine, Copenhagen, Denmark,
3Norwegian Doping Control Laboratory, Oslo University Hospital, Oslo, Norway, 4Department of Nutrition, Exercise, and
Sports, University of Copenhagen, Copenhagen, Denmark
Aim: The aim of the study was to investigate pharmacokinetics of terbutaline after oral
and inhaled administration in healthy trained male subjects in relation to doping control.
Methods: Twelve healthy well-trained young men (27 ±2 years; mean± SE) underwent
two pharmacokinetic trials that compared 10mg oral terbutaline with 4mg inhaled dry
powder terbutaline. During each trial, subjects performed 90 min of bike ergometer
exercise at 65% of maximal oxygen consumption. Blood (0–4 h) and urine (0–24 h)
samples were collected before and after administration of terbutaline. Samples were
analyzed for concentrations of terbutaline by high performance liquid chromatography
coupled to tandem mass spectrometry (HPLC-MS/MS).
Results: Pharmacokinetics differed between the two routes of administration. Serum
Cmax and area under the serum concentration-time curve (AUC) were lower after oral
administration compared to inhalation (Cmax: 4.2 ± 0.3 vs. 8.5 ± 0.7 ng/ml, P ≤ 0.001;
AUC: 422 ± 22 vs. 1308 ± 119 ng/ml × min). Urine concentrations (sum of the free
drug and the glucuronide) were lower after oral administration compared to inhalation
2 h (1100 ± 204 vs. 61 ± 10 ng/ml, P ≤ 0.05) and 4 h (734 ± 110 vs. 340 ± 48
ng/ml, P ≤ 0.001) following administration, whereas concentrations were higher for oral
administration than inhalation 12 h following administration (190 ± 41 vs. 399 ± 108
ng/ml, P ≤ 0.05). Urine excretion rate was lower after oral administration than inhalation
the first 2 h following administration (P ≤ 0.001). Systemic bioavailability ratio between
the two routes of administration was 3.8:1 (inhaled: oral; P ≤ 0.001).
Conclusion: Given the higher systemic bioavailability of inhaled terbutaline compared to
oral, our results indicate that it is difficult to differentiate allowed inhaled use of terbutaline
from prohibited oral ingestion based on urine concentrations in doping control analysis.
However given the potential performance enhancing effect of high dose terbutaline, it is
essential to establish a limit on the WADA doping list.
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INTRODUCTION
The prevalence of asthma and exercise-induced
bronchoconstriction is high in the athletic population (Carlsen
et al., 2008; Fitch et al., 2008; Price et al., 2014; Couto et al., 2015).
In endurance sport, the prevalence has been reported to be as
high as 30–50% (Parsons and Mastronarde, 2005; Aavikko and
Helenius, 2012) compared to the general population prevalence
of ∼5% in Western countries (Elers et al., 2012a). Therefore, β2-
adrenoceptor agonists (β2-agonists) are commonly prescribed
bronchodilators to athletes. Use of β2-agonists in competitive
sport is restricted by anti-doping regulations in accordance with
the World Anti-Doping Agency’s (WADA) list of prohibited
substances (The World Anti-Doping Agency, 2015b). The
2016-list of prohibited substances restricts use of all β2-agonists
except for therapeutic inhalation of salbutamol, formoterol,
and salmeterol (The World Anti-Doping Agency, 2016).
WADA has introduced urine thresholds and decision limits
for salbutamol and formoterol to discriminate therapeutic
inhaled use from prohibited supratherapeutic inhaled and
systemic use (The World Anti-Doping Agency Laboratory
Comittee, 2014; The World Anti-Doping Agency, 2016). Urine
concentrations that exceed 1200 ng/ml for salbutamol and
50 ng/ml for formoterol are presumed not to be intended
therapeutic use and is considered an adverse analytical finding
(AAF). In 2014, β2-agonists accounted for 4% (122/3079) of
AAF reported by WADA accredited doping control laboratories.
While several pharmacokinetic studies have made it possible to
establish urinary thresholds and decision limits for salbutamol
and formoterol (Sporer et al., 2008; Elers et al., 2012a,b;
Hostrup et al., 2014a; Haase et al., 2015), no urine threshold or
decision limit exists for terbutaline. Of the 122 AAFs involving
β2-agonists in 2014, terbutaline accounted for 76%, whereas
salbutamol and formoterol only accounted for 12% together
(The World Anti-Doping Agency, 2014a).
Terbutaline is commonly prescribed to athletes with asthma
and exercise-induced bronchoconstriction in Northern Europe.
As of 2016, athletes must obtain a therapeutic use exemption
(TUE) to use inhaled terbutaline (The World Anti-Doping
Agency, 2015a). Because no urinary threshold and decision
limit exist for terbutaline, athletes who have acquired a TUE
for terbutaline have an open window for supratherapeutic
misuse. This is problematic since high-dose inhalation and
oral administration of terbutaline have been shown to increase
maximal sprint ability and muscle force (Hostrup et al., 2014a,b;
Kalsen et al., 2016). While the pharmacokinetics of terbutaline
is well-described (Nyberg, 1984; Nyberg and Kennedy, 1984;
Borgström et al., 1989; Schmekel et al., 1992; Elers et al.,
2012a), data on its pharmacokinetics in relation to doping
control are insufficient. Elers et al. (2012a) observed that
urine and serum concentrations were similar after therapeutic
inhalation of 2mg and prohibited oral administration of 10mg
at rest in asthmatic and non-asthmatic men, making it difficult
to discriminate therapeutic inhaled use from oral misuse in
doping control analysis (Elers et al., 2012a). A limitation of
that study in relation to doping control analysis, however,
was that only serum and urine concentrations were measured,
whereas absorption and excretion of terbutaline were not.
Likewise, the administered dose was not the daily maximal
recommended dose as stated in the manufacturer’s summary of
product characteristics nor was it equipotent to the maximal
allowed daily dose of salbutamol as stated by The World
Anti-Doping Agency (2016). Furthermore, concentrations of
terbutaline were measured at rest and not in conjunction with
exercise, which is of relevance since asthmatic athletes often
inhale their medication prior to training or competition as
prophylaxes against bronchoconstriction (McKenzie and Fitch,
2011). Exercise increases metabolism and heat production, both
of which may affect uptake, concentration and excretion of
β2-agonists. Schmekel et al. (1992) observed that the rate of
pulmonary absorption was faster during exercise than at rest. In
addition, exercise-induced sweating may affect hydration status
and urine specific gravity (USG; Kurdak et al., 2010; Fortney et al.,
1988). Currently, threshold values for prohibited substances are
adjusted for the specific gravity of urine samples only in terms of
endogenous threshold substances (19-norandrosterone, glycerol)
when dealing with doping analysis (McKenzie and Fitch, 2011;
TheWorld Anti-Doping Agency Laboratory Comittee, 2014; The
World Anti-Doping Agency, 2014b). Studies have shown that
urine concentrations of β2-agonists are partially related to the
specific gravity (Sporer et al., 2008; Hostrup et al., 2012), because
concentrated urine samples can lead to a higher concentration
of the drug in urine. This may pose a problem as it can
lead to a false positive sample. The relationship between the
specific gravity of the urine sample and the concentration of β2-
agonists, especially after exercise, has therefore to be investigated
more comprehensively. Taken together, there is still a need to
investigate the pharmacokinetics of terbutaline with a setup
applicable for training and exercise with respect to doping control
analysis.
The purpose of the present study was to investigate the
pharmacokinetics of terbutaline after therapeutic inhalation and
prohibited oral ingestion in healthy trained subjects in samples
collected during and after 90-min of strenuous cycling. In
addition, we investigated the relation between USG of urine
samples and concentrations of terbutaline.
MATERIALS AND METHODS
Subjects and Ethical Approval
Fourteen healthy well-trained men were included in the study.
Subject characteristics are presented in Table 1. Subjects were
non-smokers without chronic diseases. All subjects received
detailed written and oral information on the study and
gave oral and written consent. The study was performed in
accordance with the Helsinki-II-Declaration and was approved
by the Regional Ethics Committee of The Capital Region of
Denmark (H-2-2014-069) and the Danish Health and Medicines
Authority (EudraCT number: 2014-002140-40). The study was
monitored in accordance with the GCP-ICH guidelines (Good
Clinical Practice; ICH Harmonised Tripartitte Guideline, 1994)
in collaboration with the GCP-unit of Copenhagen University
Hospital.
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Experimental Design
Screening Procedures
Before the pharmacokinetic trials, subjects underwent a
screening at the clinic. At the screening, subjects were
examined by a medical doctor and electrocardiography (ECG)
was performed (Schiller AT-10 plus, Schiller, Switzerland).
Furthermore, subjects’ body composition was measured by
dual X-ray absorbance (Lunar DEXA-scan, GE Healthcare,
United Kingdom) and lung function with a spirometer (EasyOne
Spirometer, NDD, Switzerland). Lastly, subjects’ maximal oxygen
consumption ( V˙O2max ) and performance were determined
during an incremental bike ergometer (Lode Ergometer,
Netherlands) test to exhaustion. Prior to the test, subjects
warmed up at 100, 150, and 200W for 4 min at each workload.
The incremental test started at 150W and increased 30W every
min until exhaustion. Subjects were told to keep a cadence of 80–
100 rpm during the test. During the warm-up and incremental
test, gas exchange was measured breath-by-breath (Oxycon Pro,
CareFusion, CA, United States).
Pharmacokinetic Intervention
The pharmacokinetic intervention was an open-labeled
crossover study that investigated the pharmacokinetics of
terbutaline after dry powder inhalation of 4mg (Bricanyl
TABLE 1 | Subject characteristics (n = 12).
Age (yrs) 27± 2
Height (cm) 183± 2
Weight (kg) 79± 2
FVC (l) 5.83± 0.25
FEV1 (l) 4.83± 0.22
FEV1/FVC-ratio 0.82± 0.02
VO2–max (ml/min/kg) 54± 2
Body fat (%) 17± 2
Lean Body Mass (kg) 66± 2
FVC, Forced Vital Capacity; FEV1, Forced Expiratory Volume in 1 second; VO2max ,
Maximal oxygen consumption. Values are means ± SEM.
Turbohaler, AstraZeneca, Denmark) and oral ingestion of 10mg
(Bricanyl Retard, AstraZeneca, Denmark) in healthy trained
men that performed exercise (Figure 1). The administered
dosage of inhaled terbutaline did not exceed the maximal
daily-recommended dose of 6mg as stated by the manufacturer.
Furthermore, the used dose of 4mg terbutaline is equipotent to
the maximal daily-allowed dose of salbutamol as stated by The
World Anti-Doping Agency (2016). The administered dosage
of oral terbutaline was 10 mg, which is the in-between dose in
relation to the accumulated daily dose, 15 mg, as recommended
by the manufacture, and the 7.5mg that is given per
administration.
The experimental protocol consisted of two trials that were
separated by at least 1 week to ensure complete washout of
terbutaline (Borgström et al., 1989). At the first trial, 10mg
terbutaline was administrated orally as two tablets, and at
the second trial, 4mg inhaled dry powder terbutaline was
administrated as 8 puffs as a single dose (0.5mg/puff). Subjects
consumed 200ml water after administration. The inhalation
procedure was trained with all participants before inhalation of
the drug. Prior to administration of terbutaline, subjects received
a standardized meal of 2 cc (85 g) oatmeal, a teaspoon of white
sugar and 500ml partly skimmed milk (total 2.377 kJ) with
300ml of water. 30 min later the drug was administrated. After
administration of study drugs, subjects exercised for 90 min at
an intensity corresponding to 65% of their V˙O2max (186 ±
11 W) on a bike ergometer. At the end of exercise, subjects
received 500ml of water with protein, as to mimic post-exercise
protein substitution. For the next 4½ h, subjects remained
inactive.
Six hours after administration of study drugs, subjects were
allowed to drink and eat without restrictions.
Blood samples (9ml) were collected 15, 30, 60, 120, 180, and
240 min after administration of terbutaline. Blood samples were
kept at 5◦C for 30min after which they were spun at 3000 rpm for
15 min. Serum was then collected in 2.5ml cryo tubes and frozen
at−80
◦
C until analysis.
Urine samples were collected in 40ml aliquots 2, 4, 6, 12,
and 24 h after administration of terbutaline. The aliquots were
FIGURE 1 | Experimental overview.
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immediately frozen and stored at until −80◦C analysis. Samples
12 and 24 h after administration were collected by the subjects’
and frozen at −20◦C until delivery the following day to the
department, where they were stored at−80◦C.
Analysis of Serum and Urine
Serum and urine samples were analyzed by theWADA accredited
Norwegian Doping Control Laboratory in Oslo, Norway.
Samples were shipped from Bispebjerg University Hospital,
Copenhagen, Denmark on dry ice keeping the temperature
at −80◦C until arrival at the Norwegian Doping Control
Laboratory. Concentrations of terbutaline in serum and urine
were quantified by high performance liquid chromatography
coupled to tandem mass spectroscopy using a method described
in a former study by Elers et al. (2012a) with some minor
modifications. In brief, 0.5 ml of urine was diluted with 1.5 ml
of deionized water, and 30 µl internal standard solution (d9-
terbutaline; Sigma, Schnelldorf, Germany, 5 µg/ml in methanol)
was added. After addition of 2 M sodium acetate buffer pH 5, 25
µl β-glucuronidase from E. coli (Roche Diagnonstics, Mannheim,
Germany) was added. Samples were incubated for 1 h at 55◦C.
Afterwards samples were applied onto Oasis-MCX solid-phase
extraction columns (60mg;Waters, Milford,Massachusetts). The
columns were conditioned with 2 ml methanol and afterwards 2
ml deionized water. After loading of the samples, the columns
were washed with 2 ml 0.1 M HCl and afterwards with 2 ml
methanol. Analytes were eluated with 2 ml NH3/methanol (5:95,
v/v), and samples were evaporated to dryness. Residues were
dissolved in 150 µl water/acetonitrile (95:5, v/v). Sample analysis
was performed on a Thermo Surveyor HPLC system coupled
to a Thermo TSQ Quantum mass spectrometer (Thermo, San
Jose, California). For chromatographic separation a 150 × 1.2
mm, 3 µm Betasil C8 column (Thermo) was used. Analytes were
separated using the following gradient of water/acetonitrile (95:5,
v/v) with 5 mM ammoniumformiate (A) and water/acetonitril
(5:95, v/v) with 5 mM ammoniumformiate (B) at a flow rate
of 200 µl/min: 0% B (0 min), 0% B (1 min), 80% B (10
min), 80% B (12 min). The mass spectrometer was operated in
positive electrospray ionization mode. ESI product ion scan of
terbutaline in positive ionization is illustrated in Figure 2. The
following transition reactions were monitored (collision energy):
226.2–152.2 (21 V), 226.2–125.2 (32 V), 226.2–107.2 (41 V)
(for terbutaline), and 235.2–153.2 (18 V) (for d9-terbutaline;
Figure 3). Quantification of terbutaline was performed by using
a 5-point calibration curve covering a concentration range from
5 to 1000 ng/ml. Urine samples exceeding 1000 ng/ml were
appropriately diluted and reanalyzed. Quantification of serum
terbutaline followed the same analytical procedures as described
for urine, with some adjustments. The 5-point calibration
curve was prepared in Autonorm serum (Sero, Billingstad,
Norway), and the calibration range was between 1 and 10 ng/ml.
Internal standard addition was adjusted (50µl d9-terbutaline, 0.1
µg/ml in methanol). Residues after solid phase extractions were
dissolved in 75 µl water/acetonitrile (95:5, v/v). Serum samples
exceeding the range of the calibration curve were appropriately
diluted and reanalyzed.
Validation demonstrated suitability of the method in
accordance with WADA’s technical documents (The World
Anti-Doping Agency Laboratory Comittee, 2014).
Pharmacokinetic Calculations
The bioavailability ratio F, between oral and inhaled
administration of terbutaline was calculated from the total
urine excretion of unchanged terbutaline using the following
equation (Kampmann et al., 2011):
F =
U∞Oral
DoseOral
×
DoseInhalation
U∞Inhalation
FIGURE 2 | ESI product ion scan of terbutaline in positive ionization (m/z 226 [M+H]+, CE 20 V).
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FIGURE 3 | HPLC-MS/MS chromatograms of terbutaline (m/z 226–152, 226–107, and 226–125 [M+H]+) and d9-terbutaline as internal standard (m/z
235–153 [M+H]+) in a control sample (500ng/ml) compared to blank urine.
Where F is the bioavailability ratio between the two routes of
administration, U∞ is the urine excretion from zero to last
sample (24 h after administration) and Dose is the administered
dose for the different routes.
The impact of adjusting urine samples for USG on
concentrations was determined using the following equation
in accordance with WADA technical documents (The World
Anti-Doping Agency Laboratory Comittee, 2014):
Cadjusted = C× (0.02/(USGsample − 1))
Where the Cadjusted is the USG adjusted urine concentration, the
USGsample is the USG of the given sample, and C is the raw
unadjusted urine concentration.
Statistics
Statistical analyses were performed in SPSS version 22 (IBM,
USA). Sample size was determined for the primary response
variable (urine concentration of terbutaline) for a linear mixed
model repeated measures design. Effect size and standard
deviation were estimated from previous pharmacokinetic studies
of β2-agonists (Elers et al., 2012a; Haase et al., 2015).
The data were tested for normality using the Shapiro–Wilks
test and Q-Q plots and are presented as means ± standard error
of the mean (SEM). To estimate changes in urine concentrations
with the intervention, a three factorial linear mixed model
was used with USG, trial, and sampling time as fixed effects
and subjects as a random factor. To estimate changes in urine
excretion and serum concentrations with the intervention, a two
factorial linear mixed model was used with trial and sampling
time as fixed effects and subjects as a random factor. In case of
multiple comparisons, a Bonferroni correction was used as a post
hoc test. Differences in Cmax, Tmax, and AUC was determined
with a t-test. Pearson’s bivariate test was used to test correlation
between USG and unadjusted urine concentrations. Level of
significance was set to P ≤ 0.05.
RESULTS
Subjects and Side Effects
Twelve out of 14 subjects completed the study. Two subjects were
excluded due to social reasons leading to non-compliance with
the protocol. Terbutaline was well-tolerated regardless the route
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of administration and only minor side effects were reported by
the subjects, including tachycardia (n = 4) after inhalation of
4mg of terbutaline.
Serum Concentrations of Terbutaline
Serum concentrations of terbutaline after inhaled and oral
administration are presented in Figures 4A–C. Serum
FIGURE 4 | Serum concentrations of terbutaline after oral
administration of 10mg and inhaled administration of 4mg in healthy
trained men (n = 12). Mean serum concentrations ± SEM (A), individual
concentrations after oral administration (B), and inhalation (C). **Different (P ≤
0.01) from oral.
concentrations of terbutaline rose faster after inhaled
administration compared to oral. Observed serum Cmax and
AUC within the first 4 h after administration were higher (both P
≤ 0.001) after inhaled administration compared to oral (Table 2).
However, as illustrated in Figure 4A, serum concentrations had
not reached their peak 4 h after oral administration.
Urine Concentrations of Terbutaline
Urine concentrations of terbutaline after inhaled and oral
administration are presented in Figures 5A–F. Urine
concentrations of terbutaline were higher (P ≤ 0.001) after
inhalation compared to oral administration 2 and 4 h after
administration (Figure 5D), whereas concentrations were lower
(P ≤ 0.05) for inhalation than oral administration 12 h after
administration (Figure 5A). After oral administration, the
highest individual urine concentration was observed 12 h after
administration reaching 1308 ng/ml when unadjusted for USG,
whereas it was 2736 ng/ml 2 h following inhalation. If adjusted
for USG, the highest individual urine concentration was observed
6 h after oral administration, reaching 881 ng/ml, whereas it was
observed 2 h after inhalation, reaching 1954 ng/ml.
Urine Excretion of Terbutaline
Urine excretion rate of terbutaline after oral and inhaled
administration is presented in Figures 6A–C. Urine excretion
rate of terbutaline was higher after inhalation compared to oral
2 and 4 h after administration (P ≤ 0.001), whereas excretion
rate was lower for inhalation than oral administration 12 h
after administration (P ≤ 0.05). Total amount of terbutaline
excreted during the 24 h after administration was not different
between oral administration of 10mg and inhaled administration
of 4mg (P = 0.20; Table 2). From the total urine excretion, the
bioavailability ratio was 3.8: 1 (inhaled: oral; P ≤ 0.001).
DISCUSSION
The main finding of this study was that the peak urine
concentrations of terbutaline were higher after inhaled
administration of 4mg than oral administration of 10mg
terbutaline. For doping control purposes, the present findings
thus indicate that it is not possible to discriminate prohibited
oral ingestion of terbutaline from inhaled administration on the
basis of the concentration of terbutaline (sum of the free drug
and the glucuronide) in urine samples in relation to WADA’s
prohibited list (The World Anti-Doping Agency, 2016).
In comparison with other pharmacokinetic studies of
terbutaline (Nyberg and Kennedy, 1984; Borgström et al., 1989;
Schmekel et al., 1992; Elers et al., 2012a), our study is the first
to investigate the pharmacokinetics of terbutaline during a setup
applicable for training and exercise with respect to doping control
analysis. Despite the 2.5-fold lower nominal dose of inhaled
terbutaline compared to oral in the present study, we observed
that the urine concentrations of terbutaline were higher during
the first 8 h for inhaled administration than oral. This apparent
difference between inhaled terbutaline and oral ingestion is
possibly related to differences in bioavailability between the two
routes of administration. Indeed, we observed that serum AUC
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FIGURE 5 | Urine concentrations of terbutaline after oral administration of 10mg and inhaled administration of 4mg in healthy trained men (n = 12).
Mean ± SEM urine unadjusted (A) and adjusted (D) concentrations, individual concentrations after oral administration (B) and inhalation (C). Adjusted mean urine
concentrations (D), individual concentrations after oral administration (E) and inhalation (F). *Different (P ≤ 0.05) from oral. **Different (P ≤ 0.01) from oral. Values are
means ± SEM (A,D) and measured values (B–E).
of terbutaline was higher for 4mg inhaled terbutaline than 10mg
of oral terbutaline. This observation is in accordance with Elers
et al. (2012a), in which inhalation of 2mg terbutaline resulted
in similar peak serum concentrations as 10mg oral ingestion 0–
6 h following administration. In the present study, it could be
speculated that calculation of serum AUC between the routes
of administration was limited by a too short period of blood
sampling (0–4 h following administration). Indeed, we failed to
observe a peak for serum concentrations of terbutaline after oral
administration in some of the subjects. Nyberg et al. (Nyberg and
Kennedy, 1984) observed a Tmax of 4 h after administration of
slow-release 7.5mg tablets of terbutaline. However, we observed
that the bioavailability ratio, based on urine excretion 0–24 h after
administration, was 3.8: 1 for inhaled versus oral administration
of terbutaline, clearly indicating a pronouncedly higher systemic
bioavailability for the inhaled route.
The markedly lower systemic bioavailability of orally
administered terbutaline compared to inhaled is likely attributed
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FIGURE 6 | Mean urine excretion rates of terbutaline after oral
administration of 10mg and inhaled administration of 4mg in healthy
trained men (n = 12). (A) Individual excretions after oral administration (B)
and inhalation (C). *Different (P ≤ 0.05) from oral. **Different (P ≤ 0.01) from
oral. Values are means ± SEM (A) and measured values (B,C).
to the first pass metabolism, that oral substances undergo.
Another factor that could explain the differences between the
two routes is exercise. It is well-known, that distribution of
cardiac output changes during exercise, in which contracting
skeletal muscle is prioritized over the splanchnic region leading
to a reduction in blood flow through the gastrointestinal system
TABLE 2 | Pharmacokinetic parameters.
Oral Inhaled
Observed AUC(0−4 h)(ng/ml × min) 422±22 1308±119**
Observed Cmax(0−4 h)(ng/ml) 4.2±0.3 8.5±0.7**
Observed Tmax(0−4 h) (min) 240±0 44±5**
Urine excretion (µg) 303±43 378±30
AUC, Area Under the Curve; Cmax , Maximal Serum Concentration; Tmax , Time to maximal
Concentration. **Different (P ≤ 0.01) from oral.
(Wade et al., 1956; Williams and Leggett, 1989; Perko et al.,
1998). Exercise could as such reduce gastrointestinal absorption
of oral terbutaline. Indeed, Elers et al. (2012a) observed a higher
Cmax after oral administration of 10mg than that observed
in the present, thus indicating that the amount absorbed is
reduced by exercise (Elers et al., 2012a). On the other hand,
Schmekel et al. (1992) found Cmax after inhalation to be higher
after exercise compared to resting, which is consistent with
our results compared to Elers et al. (2012a). Furthermore,
exercise increases pulmonary blood flow, which may increase
absorption of terbutaline when administered by inhalation
(Musch et al., 1987; Schmekel et al., 1992). Accordingly, we
observed a faster Tmax following inhalation of terbutaline
than that observed by Elers et al. (2012a) in resting subjects.
This is also consistent with Schmekel et al. in which Tmax was
1 h following inhalation at rest, whereas Tmax was 30 min
during exercise (Schmekel et al., 1992). Thus, Tmax and Cmax
seem to be prolonged and lowered, respectively, by exercise
after oral administration, whereas it is faster and higher after
inhalation. Despite the different collection time points, we found
almost the same urine concentrations after oral administration
as those observed by Elers et al. and Nyberg et al. (Nyberg
and Kennedy, 1984; Elers et al., 2012a) with higher urine
concentrations after inhalation, supporting a higher uptake of
inhaled terbutaline (Elers et al., 2012a). In relation to urine
excretion only Nyberg et al. (Nyberg and Kennedy, 1984)
reported excretion rate which compared to ours was lower when
adjusted for dose.
In the present study, we observed no differences between USG
adjusted and unadjusted urine concentrations of terbutaline,
which was opposite to the results obtained by Elers et al.
(2012a) when they examined terbutaline at rest. Hostrup et al.
(2012) has shown that urine samples unadjusted for USG can
result in false positive or false negative outcomes especially
in highly concentrated urine samples of dehydrated subject.
Nonetheless, our results showed no difference, which indicate
that the subjects were not sufficiently dehydrated to affect the
USG significantly. Therefore, rehydration during exercise plays
a crucial role for USG and false positive outcomes in doping
analysis.
Terbutaline is a commonly prescribed drug in asthma
treatment and athletes are allowed to use it in and out of
competition with a TUE. Given the current WADA regulations
for β2-agonists, it is important to be able to distinguish between
routes of administration of terbutaline, because oral use is
prohibited (The World Anti-Doping Agency, 2016). This study
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was, to our knowledge, the first to investigate the oral and inhaled
route in relation to exercise. As terbutaline often is used in
conjunction with exercise and competitions, the present setup
is more applicable than previous studies conducted at rest. Our
main findings show, that the routes of administered terbutaline
cannot be distinguished. However, it could be speculated that
the route is not important in relation to doping. It could as
such be debated whether or not the discrimination of prohibited
or allowed use of terbutaline should be set on the basis of
administered dosage and not on the basis of administered route
since the athlete achieve higher systemic concentrations after
inhalation compared to oral. Thus, it is more important to look
at the administered dose in relation to doping because both
oral administration and high dose inhalation of terbutaline may
increase maximal sprint ability and muscle force (Hostrup et al.,
2014a,b; Kalsen et al., 2016). In order to discriminate therapeutic
inhaled use of terbutaline from prohibited supratherapeutic use
as done for salbutamol, formoterol, and salmeterol (The World
Anti-Doping Agency, 2016) a general urinary threshold for
terbtualine is warranted. In any case, this should be investigated
further in future studies. While the dosing regimen of 8× 0.5mg
terbutaline by inhalation as a single dose administered in the
present study is higher than normal therapeutic recommendation
it does not exceed the maximal daily dose as stated in the
manufacturers summary of product characteristics. Furthermore,
the dose is equipotent to the maximal allowed dose (8 × 0.2mg)
for inhaled salbutamol on theWADA-prohibited list (TheWorld
Anti-Doping Agency, 2016). Given the potential of terbutaline
as a performance enhancing drug, a urinary threshold should be
defined for terbutaline based on urine concentrations observed
after inhalation. We suggest, that the dose of terbutaline to
be investigated should be 8 × 0.5mg, as this both includes
the highest allowed dose, as well as the majority of inter-
individual variations there might be, minimizing the risk of
false positive AAFs, as has been done for the other β2-agonists
on WADA’s prohibited list (The World Anti-Doping Agency,
2016).
In summary, the present study shows that it is not possible
to discriminate 4mg inhaled terbutaline from 10mg oral
administration of terbutaline based on urine concentrations of
terbutaline (sum of the free drug and the glucuronide) for
doping control purposes. This is likely related to the markedly
higher systemic bioavailability for inhaled compared to oral
administration of terbutaline. Given these results, any potential
urine threshold for terbutaline should be based on the systemic
response rather than the route of administration. With the
current regulations, athletes that have acquired a TUE for
terbutaline, may potentially inhale very high doses and enhance
performance. This advantage could be eliminated if a general
urinary threshold limit based on both pharmacokinetics and–
dynamics is introduced.
AUTHOR CONTRIBUTIONS
The experiment was performed at the Respiratory Research
Unit, Bispebjerg University Hospital and samples were analyzed
at the Norwegian Doping Control Laboratory, Oslo University
Hospital. All authors contributed to the conception and design
of the experiment, collection, analysis and interpretation of data,
and drafting the manuscript or revising it critically for important
intellectual content. All authors approved the final version of the
manuscript.
FUNDING
The study was performed with financial support from the World
Anti-Doping Agency.
ACKNOWLEDGMENTS
We thank the medical doctors at the Respiratory Research
Unit for their help with inclusion and side effect evaluation
and the Good Clinical Practice Unit of University Hospital of
Copenhagen for their monitoring of our study.
REFERENCES
Aavikko, A., and Helenius, I. (2012). Asthma medication is increasingly
prescribed for finnish olympic athletes-for a reason? J. Asthma 49, 744–9. doi:
10.3109/02770903.2012.709293
Borgström, L., Nyberg, L., Jönsson, S., Lindberg, C., and Paulson, J. (1989).
Pharmacokinetic evaluation in man of terbutaline given as separate
enantiomers and as the racemate. Br. J. Clin. Pharmacol. 27, 49–56.
Carlsen, K. H., Anderson, S. D., Bjermer, L., Bonini, S., Brusasco, V., Canonica,
W., et al. (2008). Treatment of exercise-induced asthma, respiratory and allergic
disorders in sports and the relationship to doping: Part II of the report from the
joint task force of European Respiratory Society (ERS) and european academy
of allergy and clinical immunolog. Allergy 63, 492–505. doi: 10.1111/j.1398-
9995.2008.01663.x
Couto,M., Stang, J., Horta, L., Stensrud, T., Severo,M.,Mowinckel, P., et al. (2015).
Two distinct phenotypes of asthma in elite athletes identified by latent class
analysis. J. Asthma 17, 1–8. doi: 10.3109/02770903.2015.1067321
Elers, J., Hostrup, M., Pedersen, L., Henninge, J., Hemmersbach, P., Dalhoff, K.,
et al. (2012a). Urine and serum concentrations of inhaled and oral terbutaline.
Int. J. Sport Med. 33, 1026–1033. doi: 10.1055/s-0032-1311590
Elers, J., Mørkeberg, J., Jansen, T., Belhage, B., and Backer, V. (2012b). High-dose
inhaled salbutamol has no acute effects on aerobic capacity or oxygen uptake
kinetics in healthy trained men. Scand. J. Med. Sci. Sport 22, 232–239. doi:
10.1111/j.1600-0838.2010.01251.x
Fitch, K. D., Sue-Chu, M., Anderson, S. D., Boulet, L.-P., Hancox, R. J., McKenzie,
D. C., et al. (2008). Asthma and the elite athlete: summary of the international
olympic committee’s consensus conference, Lausanne, Switzerland, January 22-
24 2008. J. Allergy Clin. Immunol. 122, 254–260. doi: 10.1016/j.jaci.2008.07.003
Fortney, S., Vroman, N., Beckett, W., Permutt, S., and LaFrance, N. (1988). Effect
of exercise hemoconcentration and hyperosmolality on exercise responses. J.
Appl. Physiol. 65, 519–524.
Haase, C. B., Backer, V., Kalsen, A., Rzeppa, S., Hemmersbach, P., and Hostrup, M.
(2015). The influence of exercise and dehydration on the urine concentrations
of salbutamol after inhaled administration of 1600 µg salbutamol as a single
dose in relation to doping analysis. Drug Test. Anal. doi: 10.1002/dta.1828.
[Epub ahead of print].
Hostrup, M., Kalsen, A., Bangsbo, J., Hemmersbach, P., Karlsson, S., and Backer,
V. (2014a). High-dose inhaled terbutaline increases muscle strength and
enhancesmaximal sprint performance in trainedmen. Eur. J. Appl. Physiol. 114,
2499–2508. doi: 10.1007/s00421-014-2970-2
Frontiers in Pharmacology | www.frontiersin.org 9 June 2016 | Volume 7 | Article 150
Dyreborg et al. Pharmacokinetics of Terbutaline
Hostrup, M., Kalsen, A., Hemmersbach, P., and Al, E. (2012). Intra-individual
variability in the urine concentrations of inhaled salmeterol in male subjects
with reference to doping analysis - impact of urine specific gravity correction.
J. Sport Med. Doping Stud. 2, 118. doi: 10.4172/2161-0673.1000118
Hostrup, M., Kalsen, A., Ortenblad, N., Juel, C., Mørch, K., Rzeppa, S., et al.
(2014b). β2-adrenergic stimulation enhances Ca2+ release and contractile
properties of skeletal muscles, and counteracts exercise-induced reductions
in Na+-K+-ATPase Vmax in trained men. J. Physiol. 592, 5445–5459. doi:
10.1113/jphysiol.2014.277095
ICH Harmonised Tripartitte Guideline (1994). Guideline for Good Clinical
Practice. Geneva.
Kalsen, A., Hostrup, M., Söderlund, K., Karlsson, S., Backer, V., and Bangsbo, J.
(2016). Inhaled Beta2-agonist increases power output and glycolysis during
sprinting in men.Med. Sci. Sports Exerc. 48, 39–48. doi: 10.1249/MSS.00000000
00000732
Kampmann, J. P., Brøsen K., and Simonsen U. (2011). Pharmacokinetics. Basal og
Klinisk Farmakologi, 4th Edn. Copenhagen: FADL.
Kurdak, S. S., Shirreffs, S. M., Maughan, R. J., Özgunen, K. T., Zeren, C.,
Korkmaz, S., et al. (2010). Hydration and sweating responses to hot-wather
football competition. Scand. J. Med. Sci. Sport. 20, 133–139. doi: 10.1111/j.1600-
0838.2010.01218.x
McKenzie, D., and Fitch, K. (2011). The astmatic athlete: inhaled Beta-2
agonist, sport performance, and doping. Clin. J. Sport Med. 21, 46–50. doi:
10.1097/IAE.0b013e318203c0ef
Musch, T. I., Friedman, D. B., Pitetti, K. H., Haidet, G. C., Stray-Gundersen, J.,
Mitchell, J. H., et al. (1987). Regional distribution of blood flow of dogs during
graded dynamic exercise. J. Appl. Physiol. 63, 2269–77.
Nyberg, L. (1984). Pharmacokinetic parameters of terbutaline in healthy man. An
overview. Eur. J. Respir. Dis. Suppl. 134, 149–160.
Nyberg, L., and Kennedy, B. (1984). Pharmacokinetics of terbutaline given in
slow-release tablets. Eur. J. Respir. Dis. Suppl. 134, 119–139.
Parsons, J. P., and Mastronarde, J. G. (2005). Exercise-induced
bronchoconstriction in athletes. Chest 128, 3966–3974. doi: 10.1378/chest.
128.6.3966
Perko, M. J., Nielsen, H. B., Skak, C., Clemmesen, J. O., Schroeder, T. V., and
Secher, N. H. (1998). Mesenteric, coeliac and splanchnic blood flow in humans
during exercise. J. Physiol. 513, 907–913.
Price, O. J., Hull, J. H., Backer, V., Hostrup, M., and Ansley, L. (2014). The
impact of exercise-induced bronchoconstriction on athletic performance:
a systematic review. Sports Med. 44, 1749–1761. doi: 10.1007/s40279-014-
0238-y
Schmekel, B., Borgstrom, L., and Wollmer, P. (1992).Exercise increases the rate of
pulmonary absorption of inhaled terbutaline. Chest 101, 742–745.
Sporer, B., Sheel, A., andMcKenzie, D. (2008). Dose response of inhaled salbutamol
on exercise perfomance and urine concentrations. Med. Sci. Sports Exerc. 40,
149–157. doi: 10.1249/mss.0b013e3181591df7
The World Anti-Doping Agency (2014a). Anti-Doping Testing Figures Samples
Analyzed and Reported by Accredited Laboratories in ADAMS.Montreal, QC.
The World Anti-Doping Agency (2014b). Harmonization Of Analysis And
Reporting Of Erythropoiesis Stimulating Agents (Esas) By Electrophoretic
Techniques - WADA Technical Document - TD2014EPO.Montreal, QC.
The World Anti-Doping Agency (2015a). The World Anti-doping Code,
Therapeutic Use Exemptions.Montreal, QC.
TheWorld Anti-Doping Agency (2015b). TheWorld Anti-Doping Code. Montreal,
QC.
The World Anti-Doping Agency (2016). The 2016 Prohibited List - International
Standards. Montreal, QC.
The World Anti-Doping Agency Laboratory Comittee (2014). Decision Limits for
the Confirmatory Quantification of Threshold Substances - WADA Technical
Document - TD2014DL.Montreal, QC.
Wade, O. L., Combes, B., Childs, A.W.,Wheeler, H. O., Cournand, A., and Bradley,
S. E. (1956). The effect of exercise on the splanchnic blood flow and splanchnic
blood volume in normal man. Clin. Sci. 15, 457–463.
Williams, L. R., and Leggett, R. W. (1989). Reference values for resting blood flow
to organs of man. Clin. Phys. Physiol. Meas. 10, 187–217.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Dyreborg, Krogh, Backer, Rzeppa, Hemmersbach and
Hostrup. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pharmacology | www.frontiersin.org 10 June 2016 | Volume 7 | Article 150
